{"url_path":"/sec/huma/8-k/2026-06-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1818382/0001104659-26-072980-index.html","accession_number":"0001104659-26-072980","cik":"0001818382","ticker":"HUMA","issuer_name":"Humacyte, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1818382/0001104659-26-072980-index.html","primary_entity_key":"0001818382","primary_entity_name":"Humacyte, Inc."},"word_count":140,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit**\n\n**Number** \n\n \n**Description**\n\n[1.1](tm2617224d2_ex1-1.htm)\n \n[Underwriting Agreement, dated June 10, 2026, by and among Humacyte, Inc., and Barclays Inc., BTIG, LLC and Trian Partners Group LLC, as representatives of the Underwriters.](tm2617224d2_ex1-1.htm)\n\n \n \n \n\n[5.1](tm2617224d2_ex5-1.htm)\n \n[Opinion of Covington & Burling LLP.](tm2617224d2_ex5-1.htm)\n\n \n \n \n\n[23.1](tm2617224d2_ex5-1.htm)\n \n[Consent of Covington & Burling LLP (contained in Exhibit 5.1).](tm2617224d2_ex5-1.htm)\n\n \n \n \n\n[99.1](tm2617224d2_ex99-1.htm)\n \n[Press release, dated June 10, 2026.](tm2617224d2_ex99-1.htm)\n\n \n \n \n\n[99.2](tm2617224d2_ex99-2.htm)\n \n[Press release, dated June 10, 2026.](tm2617224d2_ex99-2.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n2\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**HUMACYTE,\nINC.**\n\n \n \n \n\nDate:\nJune 11, 2026\nBy:\n /s/\nDale A. Sander\n\n \n \nName:\nDale\nA. Sander\n\n \n \nTitle:\nChief\nFinancial Officer, Chief Corporate Development Officer and Treasurer\n\n \n\n3"}